X0306 4 2020-04-03 0 0001566044 Menlo Therapeutics Inc. MNLO 0001759703 Wiley Matthew T. 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 0 1 0 0 Chief Commercial Officer Common Stock 2020-04-03 4 A 0 46394 A 113445 D Common Stock 2020-04-03 4 A 0 91430 A 204875 D Common Stock 2020-04-06 4 F 0 908 1.40 D 203967 D As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. In connection with the events described in footnote 1, each option to purchase shares of Menlo common stock that was acquired by the Reporting Person in connection with the Merger (as reported on the Form 4 filed by the Reporting Person on March 11, 2020) has been adjusted pursuant to its terms. /s/ Mutya Harsch, attorney-in-fact for Matthew Wiley 2020-04-07